Friendly female doctor holding patient hand in office

Patients & Caregivers

For Patients & Caregivers

At Aldeyra, we are working to develop safe, effective drugs that improve lives.

Dry Eye Disease & Allergic Conjunctivitis

Dry eye disease and allergic conjunctivitis are common conditions that cause red, burning, inflamed eyes. Aldeyra is developing a new potential treatment that, if approved for sale, could reduce inflammation and help patients avoid steroid use.


Proliferative Vitreoretinopathy

Proliferative vitreoretinopathy (PVR) is an eye condition that causes the retina to detach, most commonly after retinal detachment repair surgery or an eye injury. Aldeyra is developing a new potential treatment that, if approved for sale, could be the first FDA-approved drug for preventing PVR.


Sjögren-Larsson Syndrome

Sjögren-Larsson Syndrome (SLS) is a rare disease that causes intellectual disability, stiffening of the leg muscles, and seizures. It also makes a person’s skin scaly and itchy. Aldeyra is developing a topical dermal treatment that, if approved for sale, could help relieve the troubling skin problems for people with SLS.


Early Access Program

Aldeyra is committed to providing patients with access to our therapies. Find out how to request access to our investigational products here.


Clinical Trials

Check here to learn about the investigational medicines we are developing and see which studies may be recruiting patients to participate in clinical trials.